GlassScriptPhysician profile
Martha Torres
NPI 1477030526
$4,907.25
in general payments reported to CMS, 2019-2025
23 companies · $582 in 2025
The $582 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $479 · 2022: $1,391 · 2023: $1,325 · 2024: $1,130 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,879 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,878.67 |
| Education | $158.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,096.69 | 2021-2025 | |
| Lilly USA, LLC | $739.11 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $457.58 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $338.72 | 2022-2024 | Absorica Ld, Winlevi |
| Incyte Corporation | $284.80 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $269.31 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| E.R. Squibb & Sons, L.L.C. | $258.63 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $254.18 | 2023-2024 | Vtama |
| Genzyme Corporation | $200.76 | 2021-2023 | |
| Pfizer INC. | $194.22 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $172.66 | 2022-2023 | Dupixent |
| Ucb, INC. | $131.65 | 2022-2025 | Bimzelx |
| Journey Medical Corporation | $120.93 | 2023-2024 | |
| Leo Pharma INC. | $91.89 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $49.66 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $44.71 | 2025 | Vtama |
| Botanix Sb INC | $39.81 | 2025 | Sofdra |
| Amgen INC. | $37.01 | 2023-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $36.26 | 2023 | |
| Blueprint Medicines Corporation | $34.94 | 2023 | |
| Arcutis Biotherapeutics, INC. | $21.93 | 2024 | Zoryve |
| Almirall LLC | $18.16 | 2021 | |
| Galderma Laboratories, L.P. | $13.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.